Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

Biogen (NASDAQ:BIIB) shares experienced a change in market expectations as Cantor Fitzgerald revised the company's price target. The new target has been set at $206.00, a decrease from the previous ...

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Request To Download Free Sample of This Strategic Report @ Highlighted with 36 tables and 83 figures, this 153-page report ?North America Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

Fresh off a reorganization, Biogen’s research leader Jane Grogan says the biotech has to 'look outside the walls of the ...

The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of ...

Japan’s Eisai and US partner Biogen have announced today update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab (trade name Leqembi) as a treatment for early ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going to take a look at where Biogen Inc.

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.

Recent health news highlights include a review of the safety of Alzheimer's drug Leqembi, legal charges against a New York ...